Stabilized powder formulations
US6369115B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Mar 20, 2000 |
| Grant date | Apr 9, 2002 |
| Priority date | — |
| Expiry date | Mar 20, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A dry powder formulation for treatment of pulmonary conditions, via inhalation, includes an effective amount of formoterol or a salt or solvate thereof, in a dry powder form, an effective amount of fluticasone, in a dry powder form, and an excipient. A method for preparing a physically stable dry powder formulation for inhalation includes the steps of micronizing a first active polar drug, a second active non-polar drug, and a polar excipient. The second non-polar active drug is first blended with the excipient to form an intermediate mixture. The intermediate mixture is then blended with the first active polar drug. The increased separation of the polar drug and polar excipient stabilizes the formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.